REVVITY, INC Accounts Receivable, Allowance for Credit Loss, Current
REVVITY, INC (RVTY) had Accounts Receivable, Allowance for Credit Loss, Current of $47.60 million as of 2021-01-03, per its 10-K filed 2021-03-02.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2021-03-02
- 2021-01-03: Accounts Receivable, Allowance for Credit Loss, Current $47.60M.
- 2019-12-29: Accounts Receivable, Allowance for Credit Loss, Current $35.20M.
- 2018-12-30: Accounts Receivable, Allowance for Credit Loss, Current $30.60M.
- 2017-12-31: Accounts Receivable, Allowance for Credit Loss, Current $31.30M.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current | Accounts Receivable, Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2021-01-03 | $47.60M 10-K · filed 2021-03-02 | |
| 2019-12-29 | $35.20M 10-K · filed 2021-03-02 | |
| 2018-12-30 | $30.60M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $31.30M 10-K · filed 2019-02-26 | |
| 2017-01-01 | $29.20M 10-K · filed 2018-02-27 | |
| 2016-01-03 | $29.90M 10-K · filed 2017-02-28 | |
| 2014-12-28 | $32.90M 10-K · filed 2016-03-01 | |
| 2013-12-29 | $28.30M 10-K · filed 2015-02-24 | $30.20M 10-K · filed 2014-02-25 |
| 2012-12-30 | $23.40M 10-K · filed 2014-02-25 | |
| 2012-01-01 | $23.60M 10-K · filed 2013-02-26 | |
| 2011-01-02 | $23.70M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| METTLER TOLEDO INTERNATIONAL INC/ (MTD) | $30.436B | 30.62 | |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |